Kura Oncology Inc (NASDAQ:KURA) has been assigned a consensus rating of “Buy” from the nine brokerages that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating and eight have assigned a buy rating to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $30.20.

KURA has been the topic of a number of research analyst reports. Piper Jaffray Companies set a $25.00 price objective on shares of Kura Oncology and gave the company a “buy” rating in a research report on Monday, December 3rd. ValuEngine downgraded shares of Kura Oncology from a “strong-buy” rating to a “buy” rating in a research report on Thursday, January 24th. Zacks Investment Research downgraded shares of Kura Oncology from a “buy” rating to a “hold” rating in a research report on Friday, November 9th. initiated coverage on shares of Kura Oncology in a research report on Monday, November 5th. They set a “buy” rating and a $35.00 price objective on the stock. Finally, HC Wainwright reissued a “buy” rating and set a $31.00 price objective on shares of Kura Oncology in a research report on Monday, December 3rd.

In other Kura Oncology news, major shareholder Ecor1 Capital Fund Qualified, bought 40,538 shares of the company’s stock in a transaction dated Thursday, December 13th. The shares were purchased at an average price of $13.90 per share, for a total transaction of $563,478.20. The purchase was disclosed in a legal filing with the SEC, which is available at this link. 15.30% of the stock is currently owned by insiders.

Hedge funds have recently made changes to their positions in the company. Voya Investment Management LLC bought a new stake in shares of Kura Oncology during the 2nd quarter valued at $187,000. BlueMountain Capital Management LLC boosted its holdings in shares of Kura Oncology by 2,315.9% during the 3rd quarter. BlueMountain Capital Management LLC now owns 10,775 shares of the company’s stock valued at $189,000 after buying an additional 10,329 shares in the last quarter. Trexquant Investment LP bought a new stake in shares of Kura Oncology during the 3rd quarter valued at $217,000. Credit Suisse AG boosted its holdings in shares of Kura Oncology by 36.7% during the 3rd quarter. Credit Suisse AG now owns 18,142 shares of the company’s stock valued at $318,000 after buying an additional 4,869 shares in the last quarter. Finally, Bank of America Corp DE boosted its holdings in shares of Kura Oncology by 327.1% during the 2nd quarter. Bank of America Corp DE now owns 17,729 shares of the company’s stock valued at $323,000 after buying an additional 13,578 shares in the last quarter. Hedge funds and other institutional investors own 80.31% of the company’s stock.

Shares of NASDAQ KURA opened at $14.31 on Friday. The company has a current ratio of 14.76, a quick ratio of 14.76 and a debt-to-equity ratio of 0.02. Kura Oncology has a 52 week low of $10.20 and a 52 week high of $24.02. The firm has a market capitalization of $544.31 million, a P/E ratio of -9.41 and a beta of 2.97.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancers. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.

Featured Article: 52-Week High/Low Prices For Stock Selection

Analyst Recommendations for Kura Oncology (NASDAQ:KURA)

Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.